                         SEQUENCE LISTING

<110>  The Trustees of Dartmouth College
       Charite-Universitatmedizin Berlin
       Madden, Dean R.
       Cushing, Patrick R.
       Boisguerin, Prisca
       Volkmer, Rudolf
       Vouilleme, Lars
 
<120>  COMPOSITIONS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN 
       CFTR AND CAL

<130>  DC0405WO

<150>  US 61/107,438
<151>  2008-10-22

<160>  30    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa denotes Met, Phe or Trp

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa denotes Gln, Pro, or Phe

<220>
<221>  MISC_FEATURE
<222>  (3)..(4)
<223>  Xaa independently denotes Ser or Thr

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa denotes Lys or Ile

<400>  1

Xaa Xaa Xaa Xaa Xaa Ile 
1               5       


<210>  2
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  2

Cys Ala Asn Gly Leu Met Gln Thr Ser Lys Ile 
1               5                   10      


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  3

Cys Gly Leu Met Gln Thr Ser Lys Ile 
1               5                   


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  4

Cys Phe Phe Ser Thr Ile Ile 
1               5           


<210>  5
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Cys Phe Phe Thr Ser Ile Ile 
1               5           


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  6

Cys Met Gln Thr Ser Ile Ile 
1               5           


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  7

Cys Met Gln Thr Ser Lys Ile 
1               5           


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  8

Cys Trp Gln Thr Ser Ile Ile 
1               5           


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  9

Cys Trp Pro Thr Ser Ile Ile 
1               5           


<210>  10
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  10

Cys Thr Trp Gln Thr Ser Ile Ile 
1               5               


<210>  11
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  11

Cys Lys Trp Gln Thr Ser Ile Ile 
1               5               


<210>  12
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  12

Pro His Trp Gln Thr Ser Ile Ile 
1               5               


<210>  13
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  13

Phe His Trp Gln Thr Ser Ile Ile 
1               5               


<210>  14
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  14

Ser Arg Trp Gln Thr Ser Ile Ile 
1               5               


<210>  15
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  15

Cys Ala Asn Ser Arg Trp Gln Thr Ser Ile Ile 
1               5                   10      


<210>  16
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  16

Gly Leu Trp Pro Thr Ser Ile Ile 
1               5               


<210>  17
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  17

Ser Arg Trp Pro Thr Ser Ile Ile 
1               5               


<210>  18
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  18

Phe Pro Trp Pro Thr Ser Ile Ile 
1               5               


<210>  19
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with fluorescein

<400>  19

Ala Asn Ser Arg Trp Pro Thr Ser Ile Ile 
1               5                   10  


<210>  20
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  20

Ala Asn Ser Arg Trp Pro Thr Ser Ile Ile 
1               5                   10  


<210>  21
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  D-amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Modified with fluorescein

<400>  21

Trp Arg Phe Lys Lys Ala Asn Ser Arg Trp Pro Thr Ser Ile Ile 
1               5                   10                  15  


<210>  22
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  D-amino acid residue

<400>  22

Trp Arg Phe Lys Lys Ala Asn Ser Arg Trp Pro Thr Ser Ile Ile 
1               5                   10                  15  


<210>  23
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  D-amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Modified with 6-carboxy-X-rhodamine

<400>  23

Trp Arg Phe Lys Lys Ala Asn Ser Arg Trp Pro Thr Ser Ile Ile 
1               5                   10                  15  


<210>  24
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(4)
<223>  D-amino acid residue

<400>  24

Pro Asn Glu Ala Trp Pro Thr Ser Ile Ile 
1               5                   10  


<210>  25
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  D-amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  D-amino acid residue

<400>  25

Phe Asn Ala Arg Trp Gln Thr Ser Ile Ile 
1               5                   10  


<210>  26
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  D-amino acid residue

<400>  26

Phe Asn Ser Arg Trp Gln Thr Ser Ile Ile 
1               5                   10  


<210>  27
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  D-amino acid residue

<400>  27

Lys Asn Ser Arg Trp Gln Thr Ser Ile Ile 
1               5                   10  


<210>  28
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(2)
<223>  D-amino acid residue

<400>  28

Pro Asn Ser Arg Trp Gln Thr Ser Ile Ile 
1               5                   10  


<210>  29
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  D-amino acid residue

<400>  29

Ala Asn Ser Arg Trp Gln Thr Ser Ile Ile 
1               5                   10  


<210>  30
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  D-amino acid residue

<400>  30

Trp Arg Phe Lys Lys 
1               5   


